Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over the prior year quarter
Intercept updates 2020 Ocaliva Net Sales Guidance to narrow the range to $310 million to $320 million
Intercept updates 2020 non-GAAP Adjusted Operating Expenses Guidance to narrow the range to $460 million to $480 million
Productive Type A Meeting held with FDA on NASH Fibrosis Program
#ICPT announced its financial results for the quarter ended September 30, 2020.
Ocaliva® (obeticholic acid) Commercial Highlights
We recognized $79.5 million of Ocaliva net sales in the third quarter of 2020, as compared to $61.5 million in the prior year quarter. Ocaliva net sales in the third quarter of 2020 were comprised of U.S. net sales of $58.6 million and ex-U.S. net sales of $20.9 million, as compared to U.S. net sales of $45.2 million and ex-U.S. net sales of $16.3 million in the prior year quarter.
See press release HERE.
See our ICPT AmpCards HERE.